(Q41336798)

English

Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters

scientific article published on 21 September 2015

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

13

object named as

Hartwig Huland

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Claudia Hube-Magg

5

object named as

Claudia Hube-Magg

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Christina Möller-Koop

7

object named as

Christina Koop

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

9

object named as

Hans Heinzer

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

6

object named as

Sarah Minner

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

11

object named as

Guido Sauter

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Thorsten Schlomm

15

object named as

Thorsten Schlomm

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

16

object named as

Stefan Steurer

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Waldemar Wilczak

12

object named as

Waldemar Wilczak

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

4

object named as

Martina Kluth

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Maria Christina Tsourlakis

3

object named as

Maria Christina Tsourlakis

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Corinna Wittmer

10

object named as

Corinna Wittmer

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Nathaniel Melling

1

object named as

Nathaniel Melling

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

17

object named as

Till Krech

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

author name string

Erik Thomsen

2

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Markus Graefen

8

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Ronald Simon

14

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

language of work or name

0 references

publication date

21 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

36

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

1333-1340

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Global cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Repression of E-cadherin by the polycomb group protein EZH2 in cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

The polycomb group protein EZH2 is involved in progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Increased expression of EZH2, a polycomb group protein, in bladder carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Regulation and Role of EZH2 in Cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

ETS gene fusions in prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Histone deacetylases and cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

ATP-dependent chromatin remodeling: genetics, genomics and mechanisms

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Integrative genomic profiling of human prostate cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Polycomb silencers control cell fate, development and cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGV137

21 January 2018

Identifiers

10.1093/CARCIN/BGV137

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41336798&oldid=2222427286"